You are here

Home » Content

Oral Moksifloksasi n Tedavisi Sonrası Gelişen Üveit Benzeri Yan Etki

Uveitis-like Side Effect After the Use of Oral Moxifloxacin

Journal Name:

  • Smyrna Tıp Dergisi

Publication Year:

  • 2016

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Moxifloxacin is an antibiotic of the fluoroquinolone class, marketed in Turkey since 2002. It is used primarily in the treatment of bacterial sinusitis and acute exacerbations of chronic bronchitis. In this article, a 18 years old patient with bacterial sinusitis who developed oculer symptoms after oral moxifloksasin therapy, was presented. Drug-induced uveitis is relatively rare. The relationship between fluoroquinolone treatment and the occurrence of uveitis has been considered "possible", according to World Health Organization criteria, in recent studies in literature. It appears that practitioners prescribing moxifloxacin and doctors should be informed of this possible side effect, so that it may be quickly recognized, managed and reported.
Bookmark/Search this post with
Abstract (Original Language): 
Moksifloksasin 2002 yılından bu yana Türkiye'de pazarlanan florokinolon sınıfı bir antibiyotiktir. Öncelikle bakteriyel sinüzit ve kronik bronşitin akut alevlenmesi tedavisinde kullanılır. Bu makalede, bakteriyel sinüzit nedeniyle oral moksifloksasin kullanan 18 yaşında bir hastada gelişen göz semptomları sunulmuştur. İlaca bağlı üveit nadirdir. Literatürde florokinolon tedavisi ve üveit oluşumu arasındaki ilişkinin gösterildiği çalışmalar mevcut olup bu tür bir yan etkinin Dünya Sağlık Örgütü kriterlerine göre, mümkün olduğu kabul edilmiştir. Moksifloksasin reçetesi yazılmış ve göz şikayeti ile gelen hastalarda, doktorlar bu semptomları muhtemel bir yan etki olarak akılda tutmalıdır.
  • 1
38
39
  • Turkish

REFERENCES

References: 

1. Leblebicioğlu H. Microbiological and Clinical
Efficiency in New Quinolones. Ankem Derg 2002;16(3):226-31.
2. Duncombe A, Gueudry J, Massy N, Chapuzet C, Gueit I, Muraine M. Severe pseudouveitis associated with moxifloxacin therapy. J Fr Ophtalmol 2013;36(2):146-50.
3. Bettink-Remeijer M, Brouwers K, Langenhove L
van, De Waard PWT, Missotten TO, Martinez Ciriano JP and et al. Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin. Eye 2009;23(12):2260-2.
4. Bringas CR, Iglesias CD. Acute and bilateral uveitis secondary to moxifloxacin. Arch Soc Esp Oftalmol 2004;79(7):357-9.
5. Siefert HM, Kohlsdorfer C, Steinke W, Witt A.
Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats. J Antimicrob Chemother 1999;43(2):61-7.
6. Hamanaka H, Mizutani H, Asahig K, Shimizu M. Melanocyte melanin augments sparfloxacin-induced phototoxicity. J Dermatol Sci
1999;21(1):27-33.

Thank you for copying data from http://www.arastirmax.com